Novartis Oncology

Novartis Oncology
Share

Novartis Oncology

 •  November 10, 2017

Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept Significantly fewer brolucizumab patients showed signs of disease activity as well as retinal fluid (IRF and/or SRF)-key markers...

Novartis Oncology

 •  November 2, 2017

Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD Generation Study 2 aims to include a broader high-risk...

Novartis Oncology

 •  November 1, 2017

Primary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickle cell pain crisis Outcomes from matched analysis of Molecular Recurrence-free Survival from EURO-SKI and ENESTfreedom trials following Tasigna® vs....

Novartis Oncology

 •  October 31, 2017

Submission based on updated analyses from global, multi-center Phase II JULIET study, which met primary endpoint, including 6-month data to be presented at ASH 2017 Kymriah has demonstrated durable response rates in r/r DLBCL, a highly aggressive and difficult-to-treat non-Hodgkin lymphoma that is fatal in nearly 40% of patients due to relapsed or...

Novartis Oncology

 •  October 28, 2017

PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease modifying therapies for children and adolescents with MS, a population at high risk of long-term disability MS is a highly debilitating disease which touches every...

Novartis Oncology

 •  October 18, 2017

Nearly 70% of patients maintained platelet counts of >=30×109/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently stopped one or more concomitant ITP medications (including corticosteroids, danazol, azathioprine) Study establishes long-term safety profile for and...

Novartis Oncology

 •  September 9, 2017

Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Basel, September 09 2017 - Novartis, the global...

Novartis Oncology

 •  August 30, 2017

First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer treatment is the result of pioneering CAR-T cell therapy collaboration with University of Pennsylvania Reproducible, flexible and validated manufacturing...

Novartis Oncology

 •  August 27, 2017

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models that inhibition of IL-1ß impacts cancer incidence and...

Novartis Oncology

 •  August 27, 2017

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven by 24% relative reduction in risk of heart attack; a non-significant 10%...